Kiora Pharmaceuticals (FRA:7EY) Institutional Ownership: 1.48% (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7EY Kiora Pharmaceuticals Inc FRA:7EY
34 GF Score
Price €0.42
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Institutional Ownership?

Kiora Pharmaceuticals FRA:7EY 34 Institutional Ownership is 1.48% as of Jul. 24, 2026. GuruFocus rates FRA:7EY with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kiora Pharmaceuticals's institutional ownership is 1.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kiora Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kiora Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 96.90%.

Kiora Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Institutional Ownership Chart

Kiora Pharmaceuticals Historical Data

The historical data trend for Kiora Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.89 0.88 0.82 0.92 0.92 1.02 1.50 1.32 1.40 1.48
FRA:7EY
34GF Score
Kiora Pharmaceuticals Inc FRA:7EY
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.48% mean?
Kiora Pharmaceuticals (FRA:7EY) has a Institutional Ownership of 1.48% as of Jul. 24, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Institutional Ownership too high?
Kiora Pharmaceuticals' current Institutional Ownership is 1.48%. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Institutional Ownership compare to PHIO and PBM?
Kiora Pharmaceuticals' Institutional Ownership of 1.48% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Institutional Ownership is 1.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (FRA:7EY) has a current Institutional Ownership of 1.48%. The current Institutional Ownership is 1.48%. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Kiora Pharmaceuticals (FRA:7EY), the current Institutional Ownership is 1.48% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Other Exchanges KPRX:USA
Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for FRA:7EY

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price